TESARO presented new data from niraparib programs at ASCO 2019

TESARO presented new data from niraparib programs at ASCO 2019 June 4, 2019 TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), presented new data from niraparib programs at American Society of Clinical Oncology (ASCO) Annual Meeting 2019, which was held from May 31 to June 4 in Chicago, Illinois. Oral presentation: Combination of niraparib and bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer. A proof-of concept randomized controlled chemotherapy-free study: NSGO AVANOVA2/ENGOT-OV24 Category: Gynecologic Cancer Abstract No: 5505 Posters: IOLite: multipart, phase 1b, dose-finding study of the PD-1 Inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer Category: Developmental Immunotherapy and Tumor Immunobiology Abstract No: 2560 Poster Board Number: Poster Session (Board #204) Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by HRR mutational gene profile analysis Category: Gynecologic Cancer Abstract No: 5568 Poster Board Number: Poster Session (Board #391) Risk factors for progression or death in ovarian cancer patients who completed first line platinum treatment Category: Gynecologic Cancer Abstract No: 5548 Poster Board Number: Poster Session (Board #371) Recurrence of Ovarian Cancer in BRCAwt Patients Without Maintenance Therapy: Real-World Evidence Category: Gynecologic Cancer Abstract No: 5547 Poster Board Number: Poster Session (Board #370) ENGOT-OV44/FIRST study: a randomized, double-blind, phase 3 study of platinum-based therapy with TSR-042 + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 nonmucinous epithelial ovarian cancer (OC) Category: Gynecologic Cancer Abstract No: TPS5600 Poster Board Number: Poster Session (Board #420a) Real world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients Category: Gynecologic Cancer Abstract No: 5579 Poster Board Number: Poster Session (Board #402) A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration- Resistant Prostate Cancer (NCT03431350) Category: Genitourinary (Prostate) Cancer Abstract No: TPS5087 Poster Board Number: Poster Session (Board #198b) Plasma DNA repair deficient (DRD) status associates with clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/ dexamethasone (+P/D) Category: Genitourinary (Prostate) Cancer Abstract No: 5066 Poster Board Number: Poster Session (Board #178) ENGOT-Ov41/ GEICO-69-O/ ANITA trial: a phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (AT) followed by niraparib maintenance with or without AT in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months Category: Gynecologic Cancer Abstract No: TPS5599 Poster Board Number: Poster Session (Board #419b) Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): a phase 2 trial Category: Gastrointestinal (Noncolorectal) Cancer Abstract No: TPS4168 Poster Board Number: Poster Session (Board #259b) A Randomized Phase II Trial of Niraparib Plus Either Nivolumab or Ipilimumab in Patients With Advanced Pancreatic Cancer Whose Cancer Has Not Progressed on Platinum-Based Therapy Category: Gastrointestinal (Noncolorectal) Cancer Abstract No: TPS4161 Poster Board Number: Poster Session (Board #256a) About TESARO TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn. About GSK GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.

The release as fetched from its publisher. zailaboratory.com ↗